Founded in 1978 by Kiran Mazumdar-Shaw and headquartered in Bengaluru, Biocon has grown from an enzyme manufacturer into India’s largest fully-integrated, innovation-led biopharmaceutical enterprise. The company describes itself as engaged in the manufacture of biotechnology products and research services. Its operations today span four reporting segments — Biosimilars, Research Services, Generics and Novel Biologics — each with a distinct competitive position and growth trajectory.

a) Biosimilars (Biocon Biologics) — 60% of FY26 revenue. Biocon Biologics develops and markets a range of 20 biosimilars including insulins, monoclonal antibodies, and conjugated recombinant proteins across diabetology, oncology, immunology, ophthalmology, and other non-communicable diseases, ranking among the top 5 global biosimilars players and top 3 in insulins, with biomanufacturing capacity in the global top 15 and a presence spanning the U.S., Europe and emerging markets, backed by a portfolio of 10 approved biosimilars and 10 under development. This segment absorbed the transformational 2022 acquisition of Viatris’s global biosimilars business — a debt-funded deal that reshaped Biocon’s scale but also its balance sheet.

b) Research Services (Syngene) — 22% of FY26 revenue. Syngene is a global CRDMO offering integrated research, development and manufacturing services across pharma, biotech, nutrition and animal health, operating with a team of over 5,700 scientists and serving 400+ active clients, of which 16 are among the top 20 global pharma companies. Syngene is separately listed (NSE: SYNGENE), with Biocon holding a majority ~52.5% stake — an important valuation anchor discussed in §7 (SOTP).

c) Generics — 18% of FY26 revenue. Biocon is a global generics player with vertically integrated operations across APIs and complex formulations, holding the distinction of being first globally to secure approval for a generic GLP-1 drug in a regulated market, with a portfolio of 79 APIs and 83 generic formulations (22 launched in the US), and is now advancing into injectables and peptides across oncology, diabetes and obesity.

d) Novel Biologics. This portfolio includes Itolizumab, an anti-CD6 antibody launched for psoriasis in India, alongside an equity interest in Bicara Therapeutics, a US-based associate developing bifunctional antibodies for immuno-oncology. This remains a small but optionality-rich piece of the story.

The single biggest event shaping Biocon’s current fundamentals was the 2022 Viatris biosimilars acquisition — a deal that delivered global scale and regulatory infrastructure but was funded substantially through debt, pushing consolidated borrowings from roughly ₹5,147 Cr (FY22) to over ₹18,000 Cr (FY23). The subsequent three years have been about digesting that acquisition: elevated depreciation/amortisation on acquired intangibles, high interest costs, and a series of stake-sale and equity-raise transactions aimed at deleveraging — including the well-publicised exit of Viatris/Mylan from Biocon’s own shareholding via block deals (with ICICI Prudential Mutual Fund emerging as a large buyer), which pulled promoter holding down from 60.64% to 44.68% over the past two years.

Consolidated figures, ₹ Crores. Source: Company filings / Screener.

The financial arc is telling: revenue has compounded at a healthy 18% over ten years (10% TTM as the base has scaled), but profit growth has been erratic and, on a 3–5 year view, actually negative — the direct fallout of the debt-funded Viatris integration. FY26 net profit of ₹369 Cr is barely a fraction of FY25’s ₹1,429 Cr, though that FY25 number was flattered by a large one-off “other income” item (₹1,217 Cr), making TTM PAT of ₹416 Cr a more representative run-rate. Interest cost alone has risen roughly 13x since FY19, and depreciation has more than quadrupled — both direct consequences of the acquisition’s purchase-price allocation and capex cycle. ROE and ROCE remain structurally depressed (1.4% and 3.6% respectively), reflecting a business still working through its investment phase rather than harvesting it.

A 10-year FCFF model is used, with WACC of 12% and terminal growth of 5%, reflecting Biocon’s leveraged capital structure and the biosimilars industry’s long-run growth ceiling. Revenue growth is modelled decelerating from ~12% to ~7% as the base scales; EBITDA margin is assumed to expand gradually from ~21.5% toward 26% as Biosimilars operating leverage plays out and integration costs fade; capex and depreciation intensity are assumed to normalise down from currently elevated levels.

The base-case DCF anchors intrinsic value near ₹224/share — a meaningful ~47% below CMP of ₹426. This gap is not an anomaly; it reflects the mechanical reality that Biocon’s free cash generation has been thin and volatile through the integration years (TTM FCF was just ₹82 Cr, per §2 cash-flow data), and the model requires several years of margin recovery before FCFF becomes substantial. Bulls would argue the terminal assumptions here are conservative relative to management’s own margin-expansion guidance; bears would note that biosimilars pricing pressure in the US and EU could keep margin recovery slower than modelled. Investors should treat this DCF as a floor-anchoring exercise rather than a precise target.

Biocon’s trailing P/E of 95.5x is not directly comparable to peers because TTM earnings are depressed by heavy D&A and interest load from the Viatris integration, not by any deterioration in the underlying operating franchise. EV/EBITDA and EV/Sales are more meaningful lenses here.

*EV/EBITDA figures for peers are indicative ranges compiled from recent broker/market commentary and should be treated as approximate.

On EV/EBITDA (~23x) and EV/Sales (~4.7x), Biocon trades at a premium to volume-driven generics peers (Dr Reddy’s, Aurobindo, Zydus at 10–13x EV/EBITDA) but below the CDMO/specialty premium multiples commanded by Divi’s and Torrent. This positions Biocon as a market that is pricing it closer to a “biosimilars growth story” than a “generics value story” — a bet that is only fully vindicated if margins expand meaningfully from the current 20–21% toward the 25%+ levels its biosimilars-focused global peers achieve at scale.

Biocon trades at 2.03x book value — a modest premium that, on the surface, looks reasonable for a scaled biopharma franchise. However, the FY26 balance sheet’s ₹36,486 Cr of fixed assets and associated intangibles were substantially inflated by purchase-price allocation from the Viatris acquisition, meaning book value here embodies significant goodwill/intangible content rather than purely hard, replaceable manufacturing assets. NAV is therefore a weak standalone anchor for Biocon; it is included for completeness but should be read alongside DCF, EPV and SOTP rather than in isolation.

EPV capitalises current, normalised operating earnings in perpetuity with no growth assumption — a useful “sanity check” that strips out optimism about future scaling.

This is not unusual for a company mid-way through digesting a large, debt-funded acquisition — EPV is deliberately a conservative, no-growth lens — but it is an important discipline check: Biocon offers essentially no valuation cushion if the anticipated margin recovery is delayed or falls short.

Biocon’s diversified segment mix lends itself well to SOTP, and the ~₹296/share estimate here sits usefully between the more conservative EPV (negative) and DCF (₹224) readings — and closely echoes an independently-published community fair-value estimate of roughly ₹298/share seen elsewhere in the market. The convergence of three separate methods in the ₹220–300 band, all meaningfully below the CMP of ₹426, is the single most important valuation signal in this report.

Biocon’s medium-term growth case rests on four pillars. First, biosimilars scale-up: the company received EMA approval for a new drug-product fill-finish line for Semglee (insulin glargine) at its Malaysia facility, with supplies to Europe expected to begin from Q2FY27 — a concrete, dated catalyst. Continued rollout of Yesafili (aflibercept) and other biosimilars across US/EU markets should drive segment growth well above the group average. Second, generics diversification into injectables, peptides and GLP-1 analogues — an early-mover position given Biocon’s status as the first global company to secure a generic GLP-1 approval — offers a structurally higher-margin growth avenue than legacy small-molecule generics. Third, Syngene compounding as a steady, asset-light CRDMO annuity business, insulated from Biocon’s own leverage. Fourth, deleveraging and margin normalisation — every incremental rupee of debt reduction and every basis point of EBITDA margin recovery flows disproportionately to equity value given the current capital structure, which is precisely why the DCF/EPV/SOTP-to-CMP gap can close meaningfully faster than revenue growth alone would suggest, if execution stays on track.